All In Biotech

Drug Trial Radar · NCT07914231

A Study to Assess the Safety and Effectiveness of COL-5671-PRO Capsules in Adults With Moderate-to-Severe Plaque Psoriasis

A Parallel-group, Phase 2, Randomized, Double-blind, Placebo-controlled, 4-arm, 12-week Trial to Investigate the Efficacy, Safety, and Tolerability of COL-5671-PRO Oral Capsules in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Coultreon BiopharmaIndustry
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess how-well COL-5671-PRO works (clinical efficacy), how safe it is (safety), and how well it is tolerated (tolerability) when compared to placebo (a look-alike substance that contains no drug) in adults with moderate-to-severe plaque psoriasis Participants will take drug COL-5671 or a placebo every day for 12 weeks.

Conditions

  • Plaque Psoriasis

Interventions

  • COL-5671-PRODrug

    COL-5671-PRO oral capsules

  • PlaceboDrug

    Matching placebo to COL-5671-PRO capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of 75% in PASI score relative to baseline (PASI75) at Week 12Time frame: From enrollment to the end of treatment at 12 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Lynderm Research Inc.

    Markham, Canada

  • DermEdge Cutting-edge Dermatology

    Mississauga, Canada

  • SKiN Centre for Dermatology

    Peterborough, Canada

  • Centre de Recherche Dermatologique due Quebec Metropolitain Inc.

    Québec, Canada

  • The Centre for Dermatology

    Richmond Hill, Canada

  • Skinsense Medical Research

    Saskatoon, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.